Published in Eur J Hum Genet on March 03, 2010
Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents. Am J Hum Genet (2015) 1.50
Preconceptional genetic carrier testing and the commercial offer directly-to-consumers. Hum Reprod (2011) 1.32
Genomics and perinatal care. N Engl J Med (2012) 1.26
Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet (2013) 1.20
Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders. Eur J Hum Genet (2011) 0.95
Public views on participating in newborn screening using genome sequencing. Eur J Hum Genet (2014) 0.89
Expectations and values about expanded newborn screening: a public engagement study. Health Expect (2013) 0.86
Policy Making in Newborn Screening Needs a Structured and Transparent Approach. Front Public Health (2017) 0.85
Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. Eur J Hum Genet (2015) 0.83
Newborn screening for sickle cell disease: whose reproductive benefit? Eur J Hum Genet (2011) 0.83
Population-based preconception carrier screening: how potential users from the general population view a test for 50 serious diseases. Eur J Hum Genet (2016) 0.82
Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. Eur J Hum Genet (2013) 0.82
Public support for neonatal screening for Pompe disease, a broad-phenotype condition. Orphanet J Rare Dis (2012) 0.81
Preconceptional care: a systematic review of the current situation and recommendations for the future. Facts Views Vis Obgyn (2013) 0.79
International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Eur J Hum Genet (2016) 0.78
Reply to Ross' commentary: Reproductive benefit through newborn screening: preferences, policy and ethics. Eur J Hum Genet (2012) 0.77
A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. Genet Med (2016) 0.75
Biobank participant support of newborn screening for disorders with variable treatment and intervention options. J Community Genet (2016) 0.75
Newborn screening for pompe disease? a qualitative study exploring professional views. BMC Pediatr (2014) 0.75
Sickle cell disease in areas of immigration of high-risk populations: a low cost and reproducible method of screening in northern Italy. Blood Transfus (2014) 0.75
Whatever happened to qualitative description? Res Nurs Health (2000) 24.65
Towards systematic reviews that inform health care management and policy-making. J Health Serv Res Policy (2005) 12.22
Genetic counseling. Am J Hum Genet (1974) 4.86
Experience with screening newborns for Duchenne muscular dystrophy in Wales. BMJ (1993) 4.02
Revealing false paternity: some ethical considerations. Lancet (2001) 2.48
Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics (2006) 2.29
Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep (2004) 2.25
A vision of the future of newborn screening. Pediatrics (2006) 2.04
Genetic testing in asymptomatic minors: Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2009) 1.80
Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve (1986) 1.79
From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics (2006) 1.77
Effects of genetic screening on perceptions of health: a pilot study. J Med Genet (1992) 1.66
Incorporating newborn screening into prenatal care. Am J Obstet Gynecol (2004) 1.64
Public participation in medical policy-making and the status of consumer autonomy: the example of newborn-screening programs in the United States. Am J Public Health (1997) 1.49
Changing perspectives on the benefits of newborn screening. Ment Retard Dev Disabil Res Rev (2006) 1.41
Newborn screening for developmental disabilities: reframing presumptive benefit. Am J Public Health (2005) 1.34
Neonatal screening for sickle cell disorders: what about the carrier infants? BMJ (1996) 1.34
A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis (2006) 1.34
Carrier testing in minors: a systematic review of guidelines and position papers. Eur J Hum Genet (2006) 1.31
Ethical, legal, and social concerns about expanded newborn screening: fragile X syndrome as a prototype for emerging issues. Pediatrics (2008) 1.31
Questioning the consensus: managing carrier status results generated by newborn screening. Am J Public Health (2008) 1.27
Screening for conditions that do not meet the Wilson and Jungner criteria: the case of Duchenne muscular dystrophy. Am J Med Genet A (2006) 1.26
Understanding sickle cell carrier status identified through newborn screening: a qualitative study. Eur J Hum Genet (2009) 1.22
Genetic ignorance, moral obligations and social duties. J Med Philos (2000) 1.21
The expansion of newborn screening: is reproductive benefit an appropriate pursuit? Nat Rev Genet (2009) 1.21
Newborn screening program practices in the United States: notification, research, and consent. Pediatrics (2002) 1.14
Newborn screening: complexities in universal genetic testing. Am J Public Health (2006) 1.13
Introducing new screens: why are we all doing different things? J Inherit Metab Dis (2007) 1.04
Is my sick child healthy? Is my healthy child sick?: changing parental experiences of cystic fibrosis in the age of expanded newborn screening. Soc Sci Med (2008) 0.88
Essentially Yours: The Protection of Human Genetic Information in Australia--the impact on clinical practice and the 'new genetics'. Univ N S W Law J (2003) 0.78
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med (2012) 9.65
Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int J Epidemiol (2010) 2.44
DataSHIELD: resolving a conflict in contemporary bioscience--performing a pooled analysis of individual-level data without sharing the data. Int J Epidemiol (2010) 2.23
Research priorities. ELSI 2.0 for genomics and society. Science (2012) 2.10
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can (2007) 2.09
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.93
Genomic databases access agreements: legal validity and possible sanctions. Hum Genet (2011) 1.72
Data sharing, year 1--access to data from industry-sponsored clinical trials. N Engl J Med (2014) 1.57
Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). PLoS Comput Biol (2012) 1.55
Citizens' values regarding research with stored samples from newborn screening in Canada. Pediatrics (2012) 1.48
Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies. Int J Epidemiol (2011) 1.41
Legal approaches regarding health-care decisions involving minors: implications for next-generation sequencing. Eur J Hum Genet (2017) 1.39
Governing stem cell banks and registries: emerging issues. Stem Cell Res (2009) 1.37
Whole-genome sequencing in newborn screening programs. Sci Transl Med (2014) 1.34
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol (2013) 1.33
Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet (2013) 1.31
Questioning the consensus: managing carrier status results generated by newborn screening. Am J Public Health (2008) 1.27
Understanding sickle cell carrier status identified through newborn screening: a qualitative study. Eur J Hum Genet (2009) 1.22
The expansion of newborn screening: is reproductive benefit an appropriate pursuit? Nat Rev Genet (2009) 1.21
Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors. Fam Cancer (2009) 1.18
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet (2006) 1.17
Storing newborn blood spots: modern controversies. J Law Med Ethics (2004) 1.14
Preconception care and genetic risk: ethical issues. J Community Genet (2011) 1.13
Science and society: children and incompetent adults in genetic research: consent and safeguards. Nat Rev Genet (2002) 1.13
Mind the gap: policy approaches to embryonic stem cell and cloning research in 50 countries. Eur J Health Law (2006) 1.12
Disclosure and management of research findings in stem cell research and banking: policy statement. Regen Med (2012) 1.10
Building a data sharing model for global genomic research. Genome Biol (2014) 1.09
Power to the people: a wiki-governance model for biobanks. Genome Biol (2012) 1.08
Cohort profile: the maternal-infant research on environmental chemicals research platform. Paediatr Perinat Epidemiol (2013) 1.03
The challenge of informed consent and return of results in translational genomics: empirical analysis and recommendations. J Law Med Ethics (2014) 1.01
Biobanks: simplifying consent. Nat Rev Genet (2004) 1.01
Direct-to-consumer genome scanning services. Also for children? Nat Rev Genet (2009) 1.00
Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information. Eur J Hum Genet (2009) 0.99
Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? Eur J Hum Genet (2011) 0.98
Steering vaccinomics innovations with anticipatory governance and participatory foresight. OMICS (2011) 0.97
Informing parents about expanded newborn screening: influences on provider involvement. Pediatrics (2009) 0.97
Questioning the limits of genomic privacy. Am J Hum Genet (2012) 0.95
Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders. Eur J Hum Genet (2011) 0.95
Beyond the permissibility of embryonic and stem cell research: substantive requirements and procedural safeguards. Hum Reprod (2006) 0.93
From banking to international governance: fostering innovation in stem cell research. Stem Cells Int (2011) 0.93
Pharmacogenomic data sample collection and storage: ethical issues and policy approaches. Pharmacogenomics (2006) 0.93
Sustained interaction: the new normal for stem cell repositories? Regen Med (2011) 0.92
Locus-specific databases: from ethical principles to practice. Hum Mutat (2005) 0.92
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Policy and data-intensive scientific discovery in the beginning of the 21st century. OMICS (2011) 0.91
Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet Med (2013) 0.91
Parents' perspectives on participating in genetic research in autism. J Autism Dev Disord (2013) 0.91
What does it mean to trust a health system? A qualitative study of Canadian health care values. Health Policy (2008) 0.88
Paediatric biobanks: what makes them so unique? J Paediatr Child Health (2011) 0.87
Genomic testing in cancer: patient knowledge, attitudes, and expectations. Cancer (2014) 0.87
Recruiting terminally ill patients into non-therapeutic oncology studies: views of health professionals. BMC Med Ethics (2012) 0.87
Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening. Int J Technol Assess Health Care (2008) 0.86
Expectations and values about expanded newborn screening: a public engagement study. Health Expect (2013) 0.86
Ethics in Canadian health technology assessment: a descriptive review. Int J Technol Assess Health Care (2009) 0.86
Gene patents--more evidence needed, but policymakers must act. Nat Biotechnol (2007) 0.85
Physicians and genetic malpractice. Med Law (2002) 0.83
The ethical framing of personalized medicine. Curr Opin Allergy Clin Immunol (2014) 0.83
Emerging issues in paediatric health research consent forms in Canada: working towards best practices. BMC Med Ethics (2013) 0.83
Genetic information and life insurance: a 'real' risk? Eur J Hum Genet (2003) 0.82
Newborn blood spot screening in four countries: stakeholder involvement. J Public Health Policy (2008) 0.82
Legal and ethical approaches to stem cell and cloning research: a comparative analysis of policies in Latin America, Asia, and Africa. J Law Med Ethics (2004) 0.82
Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. Eur J Hum Genet (2013) 0.82
Ethical dimensions of genetics in pediatric neurology: a look into the future. Semin Pediatr Neurol (2002) 0.81
Examining the ethical and social issues of health technology design through the public appraisal of prospective scenarios: a study protocol describing a multimedia-based deliberative method. Implement Sci (2014) 0.81
Fostering public cord blood banking and research in Canada. Stem Cells Dev (2013) 0.81
Understanding umbilical cord blood banking: what women need to know before deciding. Womens Health Issues (2007) 0.80
Vaccines of the 21st century and vaccinomics: data-enabled science meets global health to spark collective action for vaccine innovation. OMICS (2011) 0.80
Trade-secret model: legal limitations. Science (2011) 0.80
Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider. J Community Genet (2012) 0.79
Direct-to-consumer genetic testing: driving choice? Expert Rev Mol Diagn (2010) 0.79
Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation. Curr Drug Metab (2012) 0.79
Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment. Arthritis Care Res (Hoboken) (2012) 0.79
What are some of the ELSI challenges of international collaborations involving biobanks, global sample collection, and genomic data sharing and how should they be addressed? Biopreserv Biobank (2014) 0.79
Forward Look: Tenth Anniversary of the Human Genome Sequence and 21 Century Postgenomics Global Health - A Close Up on Africa and Women's Health. Curr Pharmacogenomics Person Med (2011) 0.79
Carrier detection and clinical uncertainty: the case for public health ethics. Am J Public Health (2009) 0.79
An ethical and legal overview of pharmacogenomics: perspectives and issues. Med Law (2008) 0.78
What are the most oppressing legal and ethical issues facing biorepositories and what are some strategies to address them? Biopreserv Biobank (2011) 0.78
The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study. J Popul Ther Clin Pharmacol (2011) 0.78
Nutriproteomics and Proteogenomics: Cultivating Two Novel Hybrid Fields of Personalized Medicine with Added Societal Value. Curr Pharmacogenomics Person Med (2010) 0.78
The commercialization of genomic research in Canada. Healthc Policy (2010) 0.77